Patients with T2DM, persons at risk for AD, had a significantly lower associated risk of AD after administered exenatide, liraglutide and dulaglutide ( Conclusion Increasing evidence suggests that anti-diabetes medicine, GLP-1R agonists, have multiple neuroprotective mechanisms in AD models, such as anti-inflammation, anti-oxidative stress, reducing A aggregation/deposition and tau protein hyperphosphorylation, reducing neuronal apoptosis and neurotoxicity, increasing cell proliferation and neurogenesis, increasing synaptic plasticity, and other beneficial effects
Managing blood sugar is super important since it can affect you and the baby
By slowing digestion and signaling fullness to the brain, GLP-1s help reduce cravings, improve blood sugar control, and support sustainable weight loss
There were no increases in pancreatitis or pancreatic cancer noted [11,14]